Associations between clinical features and survival (progression-free survival (PFS) and overall survival (OS))
| PFS | OS | |||
| HR (90% CI) | p-value | HR (90% CI) | p-value | |
| FV: positive versus negative (reference) | 0.96 (0.73–1.26) | 0.395 | 1.06 (0.79–1.43) | 0.371 |
| Race: White versus non-White (reference) | 0.70 (0.45–1.11) | 0.100 | 1.03 (0.59–1.80) | 0.465 |
| Gender: male versus female (reference) | 0.81 (0.62–1.05) | 0.091 | 0.97 (0.72–1.30) | 0.427 |
| Smoking status: ever versus never (reference) | 0.80 (0.48–1.33) | 0.235 | 1.14 (0.61–2.15) | 0.363 |
| Age: <60 versus ≥60 years (reference) | 1.19 (0.88–1.60) | 0.176 | 0.96 (0.68–1.37) | 0.428 |
| Trial: yes versus no (reference) | 0.71 (0.53–0.95) | 0.026* | 0.60 (0.43–0.83) | 0.005* |
| ICI received: | ||||
| PD-L1 versus PD-1 (reference) | 0.60 (0.34–1.07) | 0.074 | 0.56 (0.28–1.12) | 0.083 |
| CTLA-4/CTLA-4 combinations versus PD-1 (reference) | 1.17 (0.77–1.78) | 0.264 | 1.26 (0.80–1.99) | 0.202 |
FV: influenza vaccination; ICI: immune checkpoint inhibitor; PD-L1: PD-1 ligand 1; PD-1: programmed cell death 1; CTLA-4: cytotoxic T-lymphocyte antigen 4. Harrell's C-statistic for PFS=0.541 and for OS=0.542.